EMA Backs First Oral IL-23 Receptor Agent for Plaque Psoriasis
The EMA's CHMP has adopted a positive opinion for the first oral IL-23 receptor-targeted therapy for plaque psoriasis, setting up a European Commission decision and bringing biologic-class mechanisti…